📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. (2023)

First Author: Readman JB

Attributed to: Mathematical and Statistical Modelling to Optimise Paediatric Medicines Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkad177

PubMed Identifier: 37283195

Publication URI: http://europepmc.org/abstract/MED/37283195

Type: Journal Article/Review

Volume: 78

Parent Publication: The Journal of antimicrobial chemotherapy

Issue: 8

ISSN: 0305-7453